ROR1 and ovarian carcinoma: These results support that the high expression of ROR1 in CSCs closely correlates with the EOC CSC vaccine efficacy and CSC vaccine may serve as an immunotherapeutic candidate for ovarian carcinoma immunoprophylaxis.